{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:45:14Z","timestamp":1791229514765,"version":"4.1.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Endocr Disord"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12902-018-0322-7","type":"journal-article","created":{"date-parts":[[2018,12,12]],"date-time":"2018-12-12T08:14:17Z","timestamp":1544602457000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Radioiodine treatment for graves\u2019 disease: a 10-year Australian cohort study"],"prefix":"10.1186","volume":"18","author":[{"given":"Erin","family":"Fanning","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5078-4980","authenticated-orcid":false,"given":"Warrick J.","family":"Inder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Mackenzie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,12,12]]},"reference":[{"key":"322_CR1","doi-asserted-by":"publisher","first-page":"2544","DOI":"10.1001\/jama.2015.16535","volume":"314","author":"HB Burch","year":"2016","unstructured":"Burch HB, Cooper DS. Management of Graves Disease A Review. JAMA. 2016;314:2544\u201354.","journal-title":"JAMA"},{"key":"322_CR2","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1056\/NEJMct1007101","volume":"364","author":"DS Ross","year":"2011","unstructured":"Ross DS. Radioiodine therapy for hyperthyroidism. N Engl J Med. 2011;364:542\u201350.","journal-title":"N Engl J Med"},{"key":"322_CR3","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1111\/j.1365-2265.2004.02152.x","volume":"61","author":"S Metso","year":"2004","unstructured":"Metso S, Jaatinen P, Huhtala H, Luukkaala T, Oksala H, Salmi J. Long-term follow-up study of radioiodine treatment of hyperthyroidism. Clin Endocrinol. 2004;61:641\u20138.","journal-title":"Clin Endocrinol"},{"key":"322_CR4","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1097\/01.mnm.0000183795.59097.42","volume":"26","author":"DE Zantut-Wittmann","year":"2005","unstructured":"Zantut-Wittmann DE, Ramos CD, Santos AO, Lima MMO, Panzan AD, Facuri FVO, et al. High pre-therapy [99mTc]pertechnetate thyroid uptake, thyroid size and thyrostatic drugs: predictive factors of failure in [131I]iodide therapy in Graves\u2019 disease. Nucl Med Commun. 2005;26:957\u201363.","journal-title":"Nucl Med Commun"},{"key":"322_CR5","doi-asserted-by":"crossref","first-page":"541","DOI":"10.5694\/j.1326-5377.2004.tb06068.x","volume":"180","author":"DJ Topliss","year":"2004","unstructured":"Topliss DJ, Eastman CJ. Diagnosis and management of hyperthyroidism and hypothyroidism. Med J Aust. 2004;180:541\u20132.","journal-title":"Med J Aust"},{"key":"322_CR6","first-page":"3611","volume":"86","author":"A Allahabadia","year":"2001","unstructured":"Allahabadia A, Daykin J, Sheppard MC, Gough SCL, Franklyn JA. Radioiodine treatment of hyperthyroidism\u2014prognostic factors for outcome. J Clin Endocrinol Metab. 2001;86:3611\u20137.","journal-title":"J Clin Endocrinol Metab"},{"key":"322_CR7","first-page":"85","volume":"82","author":"A Lewis","year":"2013","unstructured":"Lewis A, Rea T, Atkinson B, Bell P, Courtney H, McCance D, et al. Outcome of131I therapy in hyperthyroidism using a 550MBq fixed dose regimen. Ulster Med J. 2013;82:85\u20138.","journal-title":"Ulster Med J"},{"key":"322_CR8","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1097\/MNM.0000000000000770","volume":"39","author":"D Yang","year":"2018","unstructured":"Yang D, Xue J, Ma W, Liu F, Fan Y, Rong J, et al. Prognostic factor analysis in 325 patients with graves\u2019 disease treated with radioiodine therapy. Nucl Med Commun. 2018;39:16\u201321.","journal-title":"Nucl Med Commun"},{"key":"322_CR9","first-page":"3257","volume":"81","author":"Y Murakami","year":"1996","unstructured":"Murakami Y, Takamatsu J, Sakane S, Kuma K, Ohsawa N. Changes in thyroid volume in response to radioactive iodine for graves\u2019 hyperthyroidism correlated with activity of thyroid-stimulating antibody and treatment outcome. J Clin Endocrinol Metab. 1996;81:3257\u201360.","journal-title":"J Clin Endocrinol Metab"},{"key":"322_CR10","first-page":"40","volume":"83","author":"L Chiovato","year":"1998","unstructured":"Chiovato L, Fiore E, Vitti P, Rocchi R, Rago T, Dokic D, et al. Outcome of thyroid function in graves\u2019 patients treated with radioiodine: role of thyroid-stimulating and thyrotropin-blocking antibodies and of radioiodine-induced thyroid damage. J Clin Endocrinol Metab. 1998;83:40\u20136.","journal-title":"J Clin Endocrinol Metab"},{"key":"322_CR11","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1097\/MAJ.0000000000000288","volume":"348","author":"M Liu","year":"2014","unstructured":"Liu M, Jing D, Hu J, Yin S. Predictive factors of outcomes in personalized radioactive iodine (131I) treatment for graves\u2019 disease. Am J Med Sci. 2014;348:288\u201393.","journal-title":"Am J Med Sci"},{"key":"322_CR12","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1038\/nrendo.2013.193","volume":"9","author":"L Bartalena","year":"2013","unstructured":"Bartalena L. Diagnosis and management of graves disease: a global overview. Nat Rev Endocrinol. 2013;9:724\u201334.","journal-title":"Nat Rev Endocrinol"},{"key":"322_CR13","doi-asserted-by":"publisher","first-page":"3700","DOI":"10.1210\/jc.2009-0747","volume":"94","author":"F Tr\u00e4isk","year":"2009","unstructured":"Tr\u00e4isk F, Tallstedt L, Abraham-Nordling M, Andersson T, Berg G, Calissendorff J, et al. Thyroid-associated Ophthalmopathy after treatment for graves\u2019 hyperthyroidism with Antithyroid drugs or Iodine-131. J Clin Endocrinol Metab. 2009;94:3700\u20137.","journal-title":"J Clin Endocrinol Metab"},{"key":"322_CR14","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1056\/NEJM199206253262603","volume":"326","author":"L Tallstedt","year":"1992","unstructured":"Tallstedt L, Lundell G, Torring O, Wallin G, Ljunggren JG, Blomgren H, Taube A, the TSG. Occurrence of opthalmopathy after treatment for graves\u2019 hyperthyroidism. N Engl J Med. 1992;326:1733\u20138.","journal-title":"N Engl J Med"},{"key":"322_CR15","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1056\/NEJM198911163212001","volume":"321","author":"L Bartalena","year":"1989","unstructured":"Bartalena L, Marcocci C, Bogazzi F, Panicucci M, Lepri A, Pinchera A. Use of corticosteroids to prevent progresion of graves\u2019 opthalmopathy after radioiodine therapy for hyperthyroidism. N Engl J Med. 1989;321:1349\u201352.","journal-title":"N Engl J Med"},{"key":"322_CR16","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1530\/EC-15-0119","volume":"5","author":"M Subramanian","year":"2016","unstructured":"Subramanian M, Baby MK, Seshadri KG. The effect of prior antithyroid drug use on delaying remission in high uptake graves\u2019 disease following radioiodine ablation. Endocr Connect. 2016;5:34\u201340.","journal-title":"Endocr Connect"},{"key":"322_CR17","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1530\/EJE-07-0450","volume":"158","author":"P Laurberg","year":"2008","unstructured":"Laurberg P. TSH-receptor autoimmunity in graves \u2019 disease after therapy with anti-thyroid drugs , surgery , or radioiodine\u00a0: a 5-year prospective randomized study. Eur J Endocrinol. 2008;158:69\u201375.","journal-title":"Eur J Endocrinol"},{"key":"322_CR18","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1056\/NEJM198408163110702","volume":"311","author":"V Sridama","year":"1984","unstructured":"Sridama V, McCormick M, Kaplan E, Fauchet RDL. Long-term follow-up study of compensated low-dose I131 therapy for graves\u2019 disease. N Engl J Med. 1984;311:426\u201332.","journal-title":"N Engl J Med"},{"key":"322_CR19","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1056\/NEJM199801083380201","volume":"338","author":"L Bartalena","year":"1998","unstructured":"Bartalena L, Marcocci C, Bogazzi F, Manetti L, Tanda ML, Dell\u2019Unto E, et al. Relation between therapy for hyperthyroidism and the course of graves\u2019 Ophthalmopathy. N Engl J Med. 1998;338:73\u20138.","journal-title":"N Engl J Med"},{"key":"322_CR20","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1111\/j.1365-2265.2008.03279.x","volume":"69","author":"SH Acharya","year":"2008","unstructured":"Acharya SH, Avenell A, Philip S, Burr J, Bevan JS, Abraham P. Radioiodine therapy (RAI) for graves\u2019 disease (GD) and the effect on ophthalmopathy: a systematic review. Clin Endocrinol. 2008;69:943\u201350.","journal-title":"Clin Endocrinol"}],"container-title":["BMC Endocrine Disorders"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-018-0322-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12902-018-0322-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-018-0322-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,11]],"date-time":"2019-12-11T19:12:24Z","timestamp":1576091544000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcendocrdisord.biomedcentral.com\/articles\/10.1186\/s12902-018-0322-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["322"],"URL":"https:\/\/doi.org\/10.1186\/s12902-018-0322-7","relation":{},"ISSN":["1472-6823"],"issn-type":[{"value":"1472-6823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"14 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethics approval was obtained from the Metro South Human Research Ethics Committee (Reference number: LNR\/QMS\/43580). All necessary permissions to access medical records from the Princess Alexandra Hospital were obtained. Consent to participate was not a requirement.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"94"}}